Abstract Antibody-mediated rejection (AMR), including chronic AMR (cAMR), causes~ 50%
of kidney allograft losses each year. Despite attempts to develop well-tolerated and effective …

Despite significant advances in the field of transplantation in the past two decades, current
clinically available therapeutic options for immunomodulation remain fairly limited. The …

Abstract The Sensitization in Transplantation: Assessment of Risk workgroup is a
collaborative effort of the American Society of Transplantation and the American Society of …

Sensitized kidney transplant recipients experience high rates of antibody-mediated rejection
due to the presence of donor-specific antibodies and immunologic memory. Here we show …

Introduction Antibody-mediated rejection (ABMR) is a leading cause of kidney allograft
failure. Its therapy continues to be challenge, and no treatment has been approved for the …

There is an urgent need for therapeutic interventions for desensitization and antibody-
mediated rejection (AMR) in sensitized patients with preformed or de novo donor-specific …

Advances in hematopoietic stem cell transplant (HSCT) have led to changes in the approach
to donor selection. Many of these new approaches result in greater HLA loci mismatching …

The presence of anti-human leucocyte antigen (HLA) antibodies in the potential solid organ
transplant recipient's blood is one of the main barriers to access to a transplantation. The …

Background Xenotransplantation has made tremendous progress over the last decade.
Methods We discuss kidney and heart xenotransplantation, which are nearing initial clinical …

Sensitized patients are difficult to transplant due to pre-formed anti-donor immunity. We have
previously reported successful desensitization using carfilzomib and belatacept in a non …